DOCSLIB.ORG

UMC Utrecht Research Evaluation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UMC Utrecht Research Evaluation UMC Utrecht Research Evaluation 2013-2018 Table of contents UMC Utrecht research Self-evaluation report 3 Self-evaluation strategic research program Brain 33 Self-evaluation report strategic research program Cancer 82 Self-evaluation report strategic research program Child Health 150 Self-evaluation report strategic research program Circulatory Health 218 Self-evaluation report strategic research program Infection & Immunity 294 Self-evaluation report strategic research program Regenerative Medicine & Stem Cells 352 UMC Utrecht research Self-evaluation report (2013-2018) Foreword 5 1. Mission, strategy & general organisation 6 1.1 Mission 6 1.2 Strategy 2015-2020 ‘Connecting U’ 6 1.3 Executive Board 6 1.4 Supervisory Board 6 1.5 Organisation 7 1.6 Governance developments 7 1.7 Patient and public involvement 7 1.8 Educational Research 8 2. Research organisation & key figures 9 2.1 Strategic research programs 9 2.2 Management and responsibilities 10 2.3 Research FTE 11 2.4 Professorships 11 2.5 Diversity 11 2.6 Funding and earning capacity 12 2.7 Facilities 14 2.8 Partners and collaborations 14 3. Research policy & support 17 3.1 Research Office 17 3.2 Support for innovation and funding 17 3.3 Compliance and quality management of clinical research 18 3.4 Integrity 18 3.5 Data management 19 3.6 Open Science 19 3.7 Benchmark: Research evaluation practices at the UMC Utrecht 20 4. PhD programs: Graduate School of Life Sciences 22 4.1 Recruitment, selection & admission 22 4.2 PhD enrolment 22 4.3 PhD training 23 4.4 Supervision 24 4.5 Governance 24 5. SWOT analysis & future perspectives 26 5.1 Future perspectives 27 Appendix 1. Funding and earning capacity 28 Appendix 2. Funding from European Union 30 4 UMC Utrecht Research Evaluation Foreword The threefold mission of university medical centers in the Netherlands can be hard to pin down. How to combine research, education and healthcare in one organization, while ensuring the quality and impact we strive for? This cannot be achieved by just maintaining and optimizing international excellence in a few selected research areas. Neither are UMC’s just hospitals that deliver ‘last resort’ healthcare. In my view, university medical centers can best be seen as responsive research, education and healthcare organisations that are well-equipped to adapt to the ever changing scientific and healthcare landscape. And I believe the UMC Utrecht is doing a great job at that, as this self-evaluation report shows. For a start, responsiveness means having the freedom to pursue curiosity-driven research to explore new, promising research areas. For example, in the field of organoids we are at the forefront of new discoveries. Some clinical applications, such as targeted treatment of cystic fibrosis patients, have already been developed, but this technology is obviously not yet fully exploited. UMC Utrecht devotes significant research efforts to this field, building on collaborations at Utrecht Science Park, a global hub in the development of stem cell-derived organoids. Another example of a discovery that we are still exploring further, while already being applied in clinical practice, is MRI-guided radiotherapy (MR-Linac). Responsiveness to research developments also implies we identify and capitalize on breakthroughs in other scientific domains. For example, in the coming years we will try to translate the much-anticipated developments in artificial intelligence and data sciences into tangible benefits for biomedical research and healthcare, including prevention. An example of the latter is exposome sciences, a field where scientists from several faculties at Utrecht University closely collaborate. They recently received a Gravity award from the Dutch Research Council. Finally, responsiveness means that our center is in continuous dialogue with stakeholders to align ourselves with societal expectations. This dialogue takes place at many different levels and time scales and involves patient organisations, hospitals, primary care organisations, municipal authorities, research institutes, research funders, health insurers and other stakehol- ders. A recent manifestation is the agreement between UMCs and the minister of Healthcare that UMCs will develop a shared research agenda with regional partners with ample attention to prevention of disease. Of course this doesn’t imply our research should be ‘regional’ in a limitational sense of geography, knowledge and relevance. On the contrary, it recognizes that successful and efficient healthcare innovation requires multidisciplinary collaboration across networks that bring together real-world questions and world-class academic problem-solving capacity. The region seems an appropriate scale for a ‘living lab’, from which valuable, generalizable lessons can be learned. The availability of several successful networks and collaborations in the Utrecht region, such as the Health Hub, the elderly care network NUZO and the primary care network Julius Health Care Centers, will be instrumental in these endeavours. We owe our responsiveness in great part to the curiosity, dedication and ambition of our employees. Every day, researchers, doctors, nurses and others go to great lengths, sometimes in the face of big pressures, to deliver the best possible care today and create the care of tomorrow. The way we organise and evaluate our research also enhances our responsiveness. Our current strategy ‘Connecting U’, aiming for connection with patients and increasing our societal impact, already made that very explicit. One of the major governance changes in the UMC Utrecht has been the formation of six strategic research programs (focus areas) in 2010. These horizontal, division-spanning programs provide the strategic direction for our research efforts. They bring together the different phases of what we call the ‘innovation loop’: basic, translational and clinical/applied, research, with basic knowledge being translated to clinical application and with clinical questions shaping basic research. The strategic research programs have matured steadily in dynamic interaction with our ten divisions and continue to further focus their research efforts to increase their impact. Currently, our strategic research programs are of crucial importance in defining the research topics where the UMC Utrecht wants to make a difference in the next strategic period (2021-2025). In addition, they are in the lead in the process of establishing new (research) chairs. During the past years we also brought our evaluation guidelines in line with our goal of being a responsive research, educa- tion and healthcare organisation, emphasizing the societal impact of research. Science in Transition, a 2013 UMC Utrecht initiative that focuses on the ‘real’ impact of research, certainly changed the way we evaluate our scientists. This is strongly related to very similar policy changes announced this year by Dutch research funders, the association of universities (VSNU) and the Royal Academy of Sciences, recognizing the frontrunning role of UMC Utrecht in research evaluation. We are very much supported by Utrecht University and their support for Open Science and responsible research evaluation. Obviously, there is room for improvement. We critically evaluated the previous SEP report and, for example, took measures to increase our clinical trial activities in our strategic research programs. We have work to do in focusing our research efforts even more and in streamlining research support, which will take center stage in our next strategy. But all in all, I believe the UMC Utrecht is well-equipped and robustly organised to create positive impact in research and healthcare in the Utrecht region, in the Netherlands and in the world. Prof. Arno Hoes Dean and vice-chairman of the executive board, UMC Utrecht 5 UMC Utrecht Research Evaluation 1. Mission, strategy & general organisation 1.1 Mission UMC Utrecht is a leading international university medical center generating, testing, sharing, and applying knowledge on health, illness, and health care for the benefit of patients and society. UMC Utrecht was created in 2000 by merging the Academic Hospital Utrecht (founded 1875), Wilhelmina Children’s Hospital (founded 1888) and the Medical Faculty of Utrecht University (founded 1636). The merger of an academic hospital and the faculty of medicine into a new organisation with a single governance (university medical center) is a typical Dutch development which started around 20 years ago and is internationally unique. UMC Utrecht is, thus, separate from but also closely intertwined with Utrecht University, for example in the development of strategic research programs and in the appointment of professors. Binding agreements about collaboration and responsibilities are defined in a formal cooperation agreement. 1.2 Strategy 2015-2020 ‘Connecting U’ UMC Utrecht launched its “Connecting U” strategy in January 2015. This strategy elaborates on the previous strategic period “3.0” in which UMC Utrecht opted for a selected number of strategic research programs. Connecting U is all about connection: connection with patients, with general practitioners, with researchers, with each other, and connec- tion with society. To achieve its ambitions, UMC Utrecht has formulated the following two strategic objectives: • To further increase its social impact with an emphasis on the strategic research programs • To further strengthen the connection with our patients and other stakeholders (including students, citizens and other healthcare
Load more

Recommended publications
  • NPO-Fonds Presentatie Cijfers 2018
    CIJFERS 2018 Gebaseerd op 1 jaar feitelijke gegevens NPO-fonds (met uitzondering van de diverse talentontwikkelingstrajecten) !1 ALGEMEEN 2018 !2 Hoeveel aanvragen zijn er in totaal bij het NPO-fonds ingediend en toegekend? 2018 !3 TOTAAL INGEDIENDE AANVRAGEN Ontwikkeling Productie Totaal 160 153 140 120 100 89 81 80 72 60 47 40 42 40 30 24 15 20 10 9 0 Video drama Video documentaire Audio Totaal 2018 !4 TOTAAL TOEGEKENDE AANVRAGEN Ontwikkeling Productie Totaal 100 91 90 80 70 56 60 51 50 40 40 28 28 30 22 17 20 13 7 10 5 6 0 Video drama Video documentaire Audio Totaal 2018 !5 TOTAAL SLAGINGS% Ontwikkeling Productie Totaal 100% 80% 67% 67% 63% 63% 60% 59% 60% 57% 55% 54% 50% 52% 47% 40% 20% 0% Video drama Video documentaire Audio Totaal 2018 !6 Hoe is de verhouding tussen indieningen en toekenningen per omroep? 2018 !7 TOTAAL INGEDIEND PER OMROEP Ontwikkeling Productie Totaal 40 34 34 35 30 25 26 25 19 18 20 15 16 16 15 13 15 12 11 9 9 10 7 8 5 4 4 4 5 1 0 1 0 EO MAX NTR VPRO HUMAN BNNVARA AVROTROS KRO-NCRV 2018 !8 TOTAAL TOEGEKEND PER OMROEP Ontwikkeling Productie Totaal 25 20 19 20 18 18 15 13 9 10 10 9 9 10 7 8 7 5 6 5 3 3 5 2 1 0 0 0 0 EO MAX NTR VPRO HUMAN BNNVARA AVROTROS KRO-NCRV 2018 !9 2018 59% 52% 63% 69% Gemiddeld 60% 82% VPRO 80% 78% 81% NTR Totaal 0% 0% MAX 53% 50% Productie 56% !10 54% KRO-NCRV 50% OMROEP 56% HUMAN 56% Ontwikkeling 53% EO 60% 38% 75% TOTAAL SLAGINGS% PER 0% 50% BNNVARA 20% 71% AVROTROS 0% 20% 10% 90% 80% 70% 60% 50% 40% 30% Hoeveel geld is er in totaal toegekend? 2018 !11 2018 € 15.978.099 € 8.927.107 € 7.251.100
    [Show full text]
  • Jaarverslag Vereniging Kro-Ncrv
    JAARVERSLAG 2020 VERENIGING KRO-NCRV 1 Jaarverslag 2020 Inhoudsopgave Verslag van het bestuur bij de jaarrekening 2020 5 Verslag van de Raad van Toezicht 35 Jaarrekening 2020 43 Balans per 31 december 2020 44 Exploitatierekening over 2020 46 Kasstroomoverzicht over 2020 4 7 Algemene toelichting op de jaarrekening 52 Toelichting op de balans per 31 december 2020 60 Toelichting op de exploitatierekening over 2020 69 Nadere toelichtingen - Model IV - Exploitatierekening 2020 per kostendrager 82 - Model VI - Nevenactiviteiten per cluster 84 - Model VII - Sponsorbijdragen en bijdragen van derden 86 - Model VIII - Bartering 90 - Model IX - Verantwoording kosten per platform en per domein 9 1 Overige gegevens 91 Controleverklaring 92 2 Jaarverslag 2020 Jaarverslag 2020 3 1 VERSLAG VAN HET BESTUUR BIJ DE JAARREKENING 2020 The PassionJaarverslag 2020 1.1. Inleiding: het jaar 2020 en grote (sport)evenementen doorgeschoven naar van Gehandicaptenzaken, een initiatief van KRO- 3D-audiotechnieken waardoor de insectenwereld Het programma BinnensteBuiten waarin KRO-NCRV 2021. Dit bood enerzijds mogelijkheden om extra NCRV, een akkoord gekomen tussen grote belan- op unieke wijze tot leven komt en door middel van op tv, online, met (3D)podcasts en zelfs met een programma’s te maken. Anderzijds heeft dit er ook genverenigingen en de politiek om meer inclusieve Augmented Reality de insecten levensgroot in huis eigen (online) festival actief oproept om de wereld toe geleid dat er weinig ruimte was om de voorge- speeltuinen te bouwen en hebben de vragen aan kunnen worden geprojecteerd. Maar ook met het en de natuur om ons heen te ontdekken en om nomen extra investeringen in nieuw media-aanbod de Minister geresulteerd in een gebarentolk bij de You-Tube-kanaal Spot On waarbij interactie en de duurzamer te leven, is een aansprekend voorbeeld te doen en ook voor andere nieuwe initiatieven die persconferenties over de coronacrisis.
    [Show full text]
  • Yelena Myshko (Kyiv, 1985) Is a Multidisciplinary Artist Based in Zutphen, the Netherlands
    YELENA MYSHKO ////////// Ambiguous agent of change... ////////// [email protected] ////////// yelenamyshko.com Born in Kyiv, Ukraine Based in Zutphen, the Netherlands Yelena Myshko (Kyiv, 1985) is a multidisciplinary artist based in Zutphen, the Netherlands. She is exploring the social and visual phenomena of the current Zeitgeist. With both theoretical and soma immersive research methodologies she tries to find and extrapolate existential tension points within her socio-cultural environment from which she creates art and theory. AWARDS & GRANTS 2019 Kunstschouw Award, shortlisted, material prize awarded Walter Koschatzky Art-Award, nominated 2018 BLOOOM Award by Warsteiner, nominated 2017 Hendrik Muller Fonds, awarded ArtEZ Profileringsfonds, awarded 2009 HKU Jan van Scorel Fonds, awarded SOLO EXHIBITIONS 2012 Gen Y Folk: anthropology of digital culture, ROAM, Utrecht, the Netherlands (curated by Kim de Haas from Els & Nel) 2010 One Hour Art: second hour, Centraal Museum, Utrecht, the Netherlands (juried by Jos Houweling) GROUP EXHIBITIONS 2021 V International Biennial of Nude “Marko Krstov Gregović”, Public Institution Museums and galleries of Budva, Budva and Petrovac, Montenegro (curated by Dragan Mijač Brile and Milijana Istijanovic) AUSTRAL from the Virtual Realm, AUSTRAL Performance Art Festival, Buenos Aires, Argentina (curated by Hector Canonge) 2020 Wild Wild Æst, Æther Haga, the Hague, the Netherlands (curated by Marie Civikov and Voin de Voin) 2019 NULLLLL, Evenementenhal De Prodentfabriek, Amersfoort, the Netherlands
    [Show full text]
  • Factors Influencing Clinical Trial Site Selection in Europe
    BMJ Open: first published as 10.1136/bmjopen-2013-002957 on 15 November 2013. Downloaded from Open Access Research Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study) Marta Gehring,1 Rod S Taylor,2 Marie Mellody,3 Brigitte Casteels,4 Angela Piazzi,3 Gianfranco Gensini,5 Giuseppe Ambrosio6 To cite: Gehring M, ABSTRACT et al Strengths and limitations of this study Taylor RS, Mellody M, . Objectives: Applications to run clinical trials in Factors influencing clinical Europe fell 25% between 2007 and 2011. Costs, speed ▪ trial site selection in Europe: We provide systematic evidence across a large of approvals and shortcomings of European Clinical the Survey of Attitudes sample of expert professionals indicating that towards Trial sites in Europe Trial Directive are commonly invoked to explain this fostering competitiveness of European clinical (the SAT-EU Study). BMJ unsatisfactory performance. However, no hard evidence research may not require additional government Open 2013;3:e002957. is available on the actual weight of these factors or has spending/incentives. Carefully crafted harmonisa- doi:10.1136/bmjopen-2013- it been previously investigated whether other criteria tion of approvals, greater visibility of centres of 002957 may also impact clinical trial site selection. excellence via disease networks/the web, and Design: The Survey of Attitudes towards Trial sites in reduction of ‘hidden’ costs are more likely to ▸ Prepublication history for Europe (SAT-EU Study) was an anonymous, cross- boost competitiveness of European clinical this paper is available online. sectional web-based survey that systematically research.
    [Show full text]
  • Discovery of Novel Microbial Strains & the Impact of the Nagoya Protocol
    EXPERTS MEETING Discovery of Novel Microbial Strains & the Impact of the Nagoya Protocol Organized by BaseClear Thursday November 24th, 2020 All times are Central European Time (CET) AGENDA BaseClear hosts Chair: Dr. Radhika Bongoni & Dr. Derek Butler Derek Butler Radhika Bongoni Derek is the commercial director of BaseClear. Radhika is Business Developer at BaseClear, SESSION 1: DISCOVERY OF NOVEL MICROBIAL STRAINS Derek completed a bachelor’s degree in with focus on markets for application of microbial Start at 10.30 Biotechnology at Dublin City University in 1995, genomics in food, feed and pharma industries. • Unlock: An open large-scale infrastructure for exploring new horizons specialising in Genetics and Immunology. He Radhika received her Ph.D. in Food technology for research on microbial communities continued his studies at University College Cork (2014) from Wageningen University & Research Dr. Peter Schaap | Associate Professor, WUR and in 2001 received his PhD degree for work on (the Netherlands) and an MBA (2015) from Tias • Expanding the metagenomics toolbox for novel enzyme and bioactive the genetic regulation of lactic acid bacteria. In the School for Business & Society (the Netherlands). compound discovery and production same year he took up a post-doctoral position at With techno-commercial expertise, she is involved Dr. Alexander Wentzel | Senior researcher, SINTEF the University of Groningen where his work focused in business growth and market penetration by • The importance of culturomics for unraveling microbial life in extreme environments on the identification of novel enzymatic activities fostering relationships with partners. Prior to Dr. Aleksandrina Patyshakuliyeva | Product Manager – BaseClear from thermophilic bacteria. In 2004 Derek joined BaseClear, Radhika was responsible for establishing Lactrys where he worked on vaccine development dietary supplements market in western Europe, SESSION 2: THE NAGOYA PROTOCOL AND RE-CLASSIFICATION OF STRAINS in probiotic bacteria before joining BaseClear in India, South Africa and Russia.
    [Show full text]
  • Overzicht Registers Nevenfuncties Journalistieke Functionarissen
    Index registers nevenfuncties journalistieke functionarissen Peildatum 25-04-19 In januari 2019 publiceerde CIPO haar zienswijze op de toepassing van artikel 2.10 van de Governancecode Publieke Omroep 2018 voor zover het gaat over het openbaar maken van nevenfuncties van belangrijke journalistieke functionarissen. Omdat de code geen definitie van het begrip journalistiek bevat, vindt CIPO het werkbaar als mediaorganisaties voor de toepassing van het artikel aansluiten bij het systeem van de zogenoemde CCC-codes. In de registers moeten daarom in ieder geval de nevenfuncties worden vermeld van de presentatoren (of van bijvoorbeeld hoofd- of eindredacteuren) van de als journalistieke uiting aangemerkte programma’s. In aansluiting op die publicatie inventariseerde CIPO of de media-instellingen en de NPO aan artikel 2.10 toepassing hebben gegeven. In onderstaand overzicht zijn webadressen van (en een beschrijving van de routes naar) deze openbare registers opgenomen. Uit de geïnventariseerde registers blijkt dat alle twaalf mediaorganisaties (zes omroepverenigingen, drie aspirant-omroepen, twee taakomroepen en de stichting NPO) op hun websites nevenfuncties openbaar maken, dan wel er op wijzen dat met opdrachtnemers afspraken zijn gemaakt ter voorkoming van het verrichten van functies die voor de mediaorganisatie -mede gelet op de code- ongewenst zijn. Mediaorganisaties zijn primair zelf verantwoordelijk voor het naleven van de Governancecode. CIPO toetst de naleving daarvan periodiek. AVROTROS www.avrotros.nl Topfunctionarissen: Verantwoording
    [Show full text]
  • Industry Roles and Responsibilities
    IBCs in a Changing Research Landscape: A Policy Conference Industry: Roles and Responsibilities Steven A. Kradjian Executive Director, Regulatory Affairs VICAL Incorporated Progress Over 480 gene transfer trials are recorded on the OBA protocol list 86% Phase I studies 13% (64) of these in phase 2 1% (3) of these trials in phase 3. What has changed in the research landscape? Human gene transfer studies moved beyond Phase 1 research to late stage development Phase 2, Phase 3. Better characterized product Industry sponsors ~2/3 of human gene transfer clinical trials. Industry is a major partner in realizing and delivering potential benefits of gene-based medicines. Human Gene Transfer Research: FDA findings of Good Clinical Practices During 2000, FDA inspections 70 clinical study sites Industry and Academic Sponsors GCP compliance acceptable GCP deviations not different from other bioresearch programs Random Sampling of Phase 1 and 2 INDs, FDA March 2000 24 IND Sponsors of 70 Clinical Investigators Human Gene Transfer Participating in these Research INDs Independent 70.8% (17/24) 27.1% (19/70) Government (DHHS) 4.1% (1/24) 7.1% (5/70) Industry 25% (6/24) 65.7% (46/70) Gene Transfer Clinical Investigator Inspections A Comparison FDA inspected 70 randomly selected clinical investigators for GCP compliance. NAI VAI OAI GT 38% 55.9% 5.0% 2000 total 30.9% 57.1% 11.9% 2000w/o GT 21.4% 60% 18.5% 1999 28.5% 54.2% 17.1% 1998 34.9% 53% 12% Random surveillance inspections of Phase 1 and 2 gene therapy clinical trials indicates the trials were being properly conducted with fewer deviations than found in Phase 3 studies.
    [Show full text]
  • Confirmed 2021 Buyers / Commissioners
    As of April 13th Doc & Drama Kids Non‐Scripted COUNTRY COMPANY NAME JOB TITLE Factual Scripted formats content formats ALBANIA TVKLAN SH.A Head of Programming & Acq. X ARGENTINA AMERICA VIDEO FILMS SA CEO XX ARGENTINA AMERICA VIDEO FILMS SA Acquisition ARGENTINA QUBIT TV Acquisition & Content Manager ARGENTINA AMERICA VIDEO FILMS SA Advisor X SPECIAL BROADCASTING SERVICE AUSTRALIA International Content Consultant X CORPORATION Director of Television and Video‐on‐ AUSTRALIA ABC COMMERCIAL XX Demand SAMSUNG ELECTRONICS AUSTRALIA Head of Business Development XXXX AUSTRALIA SPECIAL BROADCASTING SERVICE AUSTRALIA Acquisitions Manager (Unscripted) X CORPORATION SPECIAL BROADCASTING SERVICE Head of Network Programming, TV & AUSTRALIA X CORPORATION Online Content AUSTRALIA ABC COMMERCIAL Senior Acquisitions Manager Fiction X AUSTRALIA MADMAN ENTERTAINMENT Film Label Manager XX AUSTRIA ORF ENTERPRISE GMBH & CO KG content buyer for Dok1 X Program Development & Quality AUSTRIA ORF ENTERPRISE GMBH & CO KG XX Management AUSTRIA A1 TELEKOM AUSTRIA GROUP Media & Content X AUSTRIA RED BULL ORIGINALS Executive Producer X AUSTRIA ORF ENTERPRISE GMBH & CO KG Com. Editor Head of Documentaries / Arts & AUSTRIA OSTERREICHISCHER RUNDFUNK X Culture RTBF RADIO TELEVISION BELGE BELGIUM Head of Documentary Department X COMMUNAUTE FRANCAISE BELGIUM BE TV deputy Head of Programs XX Product & Solutions Team Manager BELGIUM PROXIMUS X Content Acquisition RTBF RADIO TELEVISION BELGE BELGIUM Content Acquisition Officer X COMMUNAUTE FRANCAISE BELGIUM VIEWCOM Managing
    [Show full text]
  • Drama Directory 2014
    2014 UPDATE CONTENTS Acknowlegements ..................................................... 2 Latvia .......................................................................... 122 Introduction ................................................................. 3 Lithuania ................................................................... 125 Luxembourg ............................................................ 131 Austria .......................................................................... 4 Malta .......................................................................... 133 Belgium ...................................................................... 10 Netherlands ............................................................. 135 Bulgaria ....................................................................... 21 Norway ..................................................................... 145 Cyprus ......................................................................... 26 Poland ........................................................................ 151 Czech Republic ......................................................... 31 Portugal .................................................................... 157 Denmark .................................................................... 36 Romania ................................................................... 160 Estonia ........................................................................ 42 Slovakia ...................................................................
    [Show full text]
  • Global Guideline for the Diagnosis and Management of Rare Mould Infections
    Personal View Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology Martin Hoenigl, Jon Salmanton-García, Thomas J Walsh, Marcio Nucci, Chin Fen Neoh, Jeffrey D Jenks, Michaela Lackner, Rosanne Sprute, Abdullah M S Al-Hatmi, Matteo Bassetti, Fabianne Carlesse, Tomas Freiberger, Philipp Koehler, Thomas Lehrnbecher, Anil Kumar, Juergen Prattes, Malcolm Richardson, Sanjay Revankar, Monica A Slavin, Jannik Stemler, Birgit Spiess, Saad J Taj-Aldeen, Adilia Warris, Patrick C Y Woo, Jo-Anne H Young, Kerstin Albus, Dorothee Arenz, Valentina Arsic-Arsenijevic, Jean-Philippe Bouchara, Terrence Rohan Chinniah, Anuradha Chowdhary, G Sybren de Hoog, George Dimopoulos, Rafael F Duarte, Petr Hamal, Jacques F Meis, Sayoki Mfinanga, Flavio Queiroz-Telles, Thomas F Patterson, Galia Rahav, Thomas R Rogers, Coleman Rotstein, Retno Wahyuningsih, Danila Seidel, Oliver A Cornely With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by Lancet Infect Dis 2021 moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown Published Online effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough February 16, 2021 infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, https://doi.org/10.1016/ S1473-3099(20)30784-2 Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Section of Infectious Diseases Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to and Tropical Medicine, Medical improve prognosis.
    [Show full text]
  • Programmaschema Npo Radio 2
    PROGRAMMASCHEMA NPO RADIO 2 00:00 01:00 02:00 03:00 04:00 05:00 06:00 07:00 08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00 23:00 Van Inkel’s Wildgroei Giel Jan-Willem Start Op! Aan de slag Annemieke’s Gijs 2.4 De Wild in de Wout2Day De Staat van The Big Frank Choice Evert Duipmans & Jan-Willem Roodbeen en A-Lunch Middag Wouter van der Stasse Show Giel Beelen Bart Arens Gijs Staverman MAANDAG Jeroen van Inkel Jeroen Mulder Jeroen Kijk in de Vegte Annemieke Eddy Keur Goes Stefan Stasse Frank van ‘t Hof BNNVARA CAMPUS/BNNVARA BNNVARA BNNVARA AVROTROS SchollaardtKRO-NCRV KRO-NCRV KRO-NCRV KRO-NCRV KRO-NCRV BNNVARA ‘t Wordt Nu Laat RickvanV doet 2 Giel Jan-Willem Start Op! Aan de slag Annemieke’s Gijs 2.4 De Wild in de Wout2Day De Staat van The Big Frank Rick van Jan-Willem Roodbeen en A-Lunch Middag Wouter van der Stasse Show Kimberly Dekker Giel Beelen Bart Arens Gijs Staverman DINSDAG Velthuysen Jeroen Kijk in de Vegte Annemieke Eddy Keur Goes Stefan Stasse Frank van ‘t Hof WNL POWNED BNNVARA BNNVARA AVROTROS SchollaardtKRO-NCRV KRO-NCRV KRO-NCRV KRO-NCRV KRO-NCRV BNNVARA ‘t Wordt Nu Laat RickvanV doet 2 Giel Jan-Willem Start Op! Aan de slag Annemieke’s Gijs 2.4 De Wild in de Wout2Day De Staat van The Big Frank Rick van Jan-Willem Roodbeen en A-Lunch Middag Wouter van der Stasse Show Kimberly Dekker Giel Beelen Bart Arens Gijs Staverman WOENSDAG Velthuysen Jeroen Kijk in de Vegte Annemieke Eddy Keur Goes Stefan Stasse Frank van ‘t Hof WNL POWNED BNNVARA BNNVARA AVROTROS SchollaardtKRO-NCRV KRO-NCRV
    [Show full text]
  • Genomic Characterization of Three Marine Fungi, Including Emericellopsis Atlantica Sp
    Hagestad et al. IMA Fungus (2021) 12:21 https://doi.org/10.1186/s43008-021-00072-0 IMA Fungus RESEARCH Open Access Genomic characterization of three marine fungi, including Emericellopsis atlantica sp. nov. with signatures of a generalist lifestyle and marine biomass degradation Ole Christian Hagestad1* , Lingwei Hou2, Jeanette H. Andersen1, Espen H. Hansen1, Bjørn Altermark3, Chun Li1, Eric Kuhnert4, Russell J. Cox4, Pedro W. Crous2, Joseph W. Spatafora5, Kathleen Lail6, Mojgan Amirebrahimi6, Anna Lipzen6, Jasmyn Pangilinan6, William Andreopoulos6, Richard D. Hayes6, Vivian Ng6, Igor V. Grigoriev6,7, Stephen A. Jackson8,9, Thomas D. S. Sutton8,10, Alan D. W. Dobson8,9 and Teppo Rämä1 ABSTRACT Marine fungi remain poorly covered in global genome sequencing campaigns; the 1000 fungal genomes (1KFG) project attempts to shed light on the diversity, ecology and potential industrial use of overlooked and poorly resolved fungal taxa. This study characterizes the genomes of three marine fungi: Emericellopsis sp. TS7, wood- associated Amylocarpus encephaloides and algae-associated Calycina marina. These species were genome sequenced to study their genomic features, biosynthetic potential and phylogenetic placement using multilocus data. Amylocarpus encephaloides and C. marina were placed in the Helotiaceae and Pezizellaceae (Helotiales), respectively, based on a 15-gene phylogenetic analysis. These two genomes had fewer biosynthetic gene clusters (BGCs) and carbohydrate active enzymes (CAZymes) than Emericellopsis sp. TS7 isolate. Emericellopsis sp. TS7 (Hypocreales, Ascomycota) was isolated from the sponge Stelletta normani. A six-gene phylogenetic analysis placed the isolate in the marine Emericellopsis clade and morphological examination confirmed that the isolate represents a new species, which is described here as E.
    [Show full text]